Incomplete Retinal Vascularization After Ranibizumab Treatment of Retinopathy of Prematurity
- PMID: 28060398
- DOI: 10.3928/23258160-20161219-11
Incomplete Retinal Vascularization After Ranibizumab Treatment of Retinopathy of Prematurity
Abstract
A former 24-week-old premature infant was treated with intravitreal ranibizumab (Lucentis; Genentech, South San Francisco, CA) in one eye and conventional laser in the other eye for aggressive posterior retinopathy of prematurity in both eyes. Fluorescein angiography performed at 149 weeks of age showed persistent avascularity of the temporal peripheral retina in the ranibizumab-treated eye. This case report confirms the need for long-term follow-up of patients treated with ranibizumab monotherapy. [Ophthalmic Surg Lasers Imaging Retina. 2017;48:75-78.].
Copyright 2017, SLACK Incorporated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources